Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-01-14 | New | $2,885,000 | $2,885,000 | Equity Only | 06b | SEC link |
| 2025-01-13 | New | $2,738,355 | $2,738,355 | Equity Only | 06b | SEC link |
| 2018-09-17 | New | $70,185,418 | $70,185,418 | Equity Only | 06b | SEC link |
| 2016-11-28 | New | $15,000,000 | $15,000,000 | Equity Only | 06b | SEC link |
| 2015-10-14 | New | $37,102,500 | $37,102,500 | Equity Only | 06b | SEC link |
| 2014-08-06 | New | $4,740,000 | $4,740,000 | Equity Only | 06b | SEC link |
| 2012-12-10 | New | $11,000,000 | $11,000,000 | Equity Only | 06 | SEC link |
| Name | Role |
|---|---|
| Lawrence Alleva | Director |
| James Barrett | Director |
| Robert A. Beardsley | Director, Executive |
| Robert J. Calcaterra | Director |
| Nancy T. Chang | Director |
| Thomas Dyrberg | Director |
| Arthur Fratamico | Executive |
| Michael R. Friedman | Director |
| Eric Gulve | Director |
| Jon T. Holmlund | Executive |
| Jeffery L. Keene | Executive |
| Kevin Lokay | Director |
| Campbell Murray | Director |
| Michael Powell | Director |
| Dennis P. Riley | Executive |
| Stephen Ross | Executive |
| Michal Silverberg | Director |
| Henry Skinner | Director |
| Mel Sorensen | Director, Executive |
| J. Mel Sorensen | Director, Executive |
| Joel Sussman | Executive |
| Frank Torti | Director |